Analysis of GLP-1 drug safety and effectiveness across different patient populations provides evidence for equitable and appropriate use.
Key findingAnalysis of GLP-1 drug safety and effectiveness across different patient populations provides eviden
What the researchers found
Analysis of GLP-1 drug safety and effectiveness across different patient populations provides evidence for equitable and appropriate use.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
120 patients with IBD studied. Gastrointestinal side effects occurred in 11.5% of patients. C-reactive protein levels showed improvement.
How the study worked
In publication.
Who was studied
Adults with inflammatory bowel disease (IBD) treated with GLP-1 receptor agonists
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.
The American journal of gastroenterology, 120(5), 1152-1155
Citation
Anderson, Scott R; Ayoub, Malek; Coats, Sarah; McHenry, Scott; Tan, Tingyi; Deepak, Parakkal. (2025). Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.. The American journal of gastroenterology, 120(5), 1152-1155. https://doi.org/10.14309/ajg.0000000000003208